Drug
High-dose Cyclophosphamide
High-dose Cyclophosphamide is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
100%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
4
80%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Terminated(2)
Detailed Status
Completed2
Recruiting1
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
completed240%
recruiting120%
terminated120%
withdrawn120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_2
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
NCT06799195
terminatedphase_2
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00809341
withdrawnphase_1
High-dose Cyclophosphamide for Severe Refractory Crohn Disease
NCT01836289
completedphase_2
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
NCT00580372
completedphase_2
High Dose CHOP in Lymphoma
NCT00192764
Clinical Trials (5)
Showing 5 of 5 trials
NCT06799195Phase 2
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
NCT00809341Phase 2
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT01836289Phase 1
High-dose Cyclophosphamide for Severe Refractory Crohn Disease
NCT00580372Phase 2
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
NCT00192764Phase 2
High Dose CHOP in Lymphoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5